The Barcelona-based preclinical-stage biopharmaceutical company, RemAb Therapeutics, has developed a technology that targets non-neutralizing natural antibodies that can interfere with the immune system's response and promote pathogen growth. By removing these antibodies, RemAb's polymeric glycoconjugates can provide a new way of treating and preventing various pathological infections. The company's mission is to become a leader in the field of providing solutions for Gram-negative infections, and they plan to achieve this by introducing multiple advanced products and reaching commercialization worldwide.